[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ARCE Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100585746",false,"NCT06906380","A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1\u002F2 Study and Treated With ARD103 CAR-T Cell Therapies","Inclusion Criteria:\n\n* The participant has R\u002FR AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.\n* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study","ALL",{"count":17,"type":18},49,"ESTIMATED","OBSERVATIONAL","This study will evaluate the long-term safety of ARD103 cellular therapies",[22,23,24],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, in Relapsed or Refractory","MDS (Myelodysplastic Syndrome)","NOT_YET_RECRUITING","2025-12-04",{"date":28,"type":29},"2025-12-08","ACTUAL",{"date":31,"type":18},"2026-03-15",{"date":33,"type":18},"2040-10-31",{"name":35,"class":36},"ARCE Therapeutics, Inc.","INDUSTRY",3,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":10,"sex":15,"minAge":44,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":37},"100568402","NCT06680752","Clinical Study of ARD103 CAR-T Therapy for Patients With R\u002FR AML or MDS","A Phase 1\u002F2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","Inclusion Criteria:\n\n* Documented diagnosis of AML with either refractory or relapsed disease or diagnosis of MDS and ≥ 5% BM blasts\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic status:\n\n  * Absolute lymphocyte count (ALC) \\> 100\u002Fmm3\n* Adequate renal, hepatic, cardiac and pulmonary function:\n\n  * ALT and AST \\\u003C 3.0 × the ULN\n  * Creatinine clearance ≥ 45.0 mL\u002Fmin as estimated by Cockcroft-Gault and independent dialysis\n  * Total bilirubin ≤ 2.0 mg\u002FdL\n* Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test\n* Contraception: males and females of childbearing potential must agree to use an effective method of contraception\n* Participant is capable of giving signed informed consent\n\nExclusion Criteria:\n\n* Participants with acute promyelocytic leukemia\n* Presence of active and clinically relevant central nervous system (CNS) disorder\n* Autoimmune disease requiring immunosuppressive treatment\n* Participants with known hepatic bridging cirrhosis\n* Currently active infection with hepatitis B or C\n* Previous treatment with investigational gene or cell therapy (including CAR therapy)\n* Any active acute GvHD or systemic treatment of more than 10 mg prednisone daily (or equivalent)\n* Previous chemotherapy including biologic\u002Ftargeted therapy or immunological agents directed to the pathology within 14 days prior to screening and all along the study duration","18 Years",{"count":17,"type":18},"INTERVENTIONAL",[48,49],"PHASE1","PHASE2","This is a phase I\u002F2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.",[22,52,24],"Acute Myeloid Leukemia Refractory","RECRUITING",{"date":55,"type":29},"2025-12-10",{"date":57,"type":29},"2025-05-20",{"date":59,"type":18},"2028-12",{"name":35,"class":36},""]